Do you want to read an article? Please log in or register.
Site-specific follow-up strategy for surgically resected patients with NSCLC based on ten-year follow-up data
Lung Cancer
Related content
RECOMMENDED
Lung Cancer
Surgical and Pathological Results Following Neoadjuvant Nivolumab and Platinum-Based Chemotherapy for Locally Advanced Resectable NSCLC: A Multicentre Real-World Series From England
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Brunelli A, Hoffman R, Wotton R, Baijal S, Bhatnagar P, Clarke K, Escriu C, Fakih O, Franks K, Lodhia J, Nardini M, Naidu B, Shackcloth M
doi: 10.1016/j.cllc.2024.12.010
Asthma
ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up
Respir Med
Pini L, Caminati M, Maule M, Bagnasco D, Beghè B, Bondi B, Braido F, Cameli P, Caruso C, Crimi C, El Masri Y, Giordani J, Guarnieri G, Latorre M, Mastrototaro A, Menzella F, Micheletto C, Pini A, Piras S, Spanevello A, Vianello A, Visca D, Zappa M, Zurlo M, Paggiaro P, Blasi F, Canonica GW, Senna G, Benoni R, SANI study group
doi: 10.1016/j.rmed.2025.108198
RECOMMENDED
Lung Cancer
Long term outcomes after lobar versus sublobar resection for patients with Non-Small cell lung Cancer: Systematic review and individual patient data Meta-Analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Tasoudis P, Loufopoulos G, Manaki V, Doerr M, Agala CB, Long JM, Haithcock BE
doi: 10.1016/j.lungcan.2024.107929
RECOMMENDED
Pulmonary Hypertension
Advanced Management of Patients Undergoing Transcatheter Treatment for Pulmonary Embolism: Evidence-Based Strategies for Optimized Patient Care
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med
Costa F, Jurado-Román A, Carciotto G, Becerra-Munoz V, Márquez DT, Götzinger F, Cerrato E, Misra S, Spissu M, Pavani M, Mennuni M, Chinchilla FC, Dominguez-Franco A, Muñoz-Garcia A, Navarrete RS, Varbella F, Salinas-Sanguino P, Secemsky EA, Mahfoud F, Micari A, Alonso-Briales JH, Navarro MJ
doi: 10.3390/jcm13247780
RECOMMENDED
Lung Cancer
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Léna H, Greillier L, Cropet C, Bylicki O, Monnet I, Audigier-Valette C, Falchero L, Vergnenègre A, Demontrond P, Geier M, Guisier F, Hominal S, Locher C, Corre R, Chouaid C, Ricordel C, GFPC 08–2015 ENERGY investigators
doi: 10.1016/S2213-2600(24)00264-9
RECOMMENDED
Lung Cancer
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Thorac Oncol
Kilickap S, Baramidze A, Sezer A, Özgüroğlu M, Gumus M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Fuang HG, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, Li Y, Zhu C, Kaul M, Perez J, Seebach F, Lowy I, Pouliot JF, Kim E, Magnan H
doi: 10.1016/j.jtho.2025.03.033
RECOMMENDED
Sleep Apnea
Insights from a 10-year Australasian idiopathic hypersomnia patient data registry study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Clin Sleep Med
Anderson J, Yee BJ, Grunstein R, Matar E, Chadwick M, Machan E, Chapman J, Tai J, Saini B, Sivam S
doi: 10.5664/jcsm.11298
Lung Cancer
Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC
Clin Lung Cancer
Cantor DJ, Nimeiri H, Horn L, West M, Ben-Shachar R, Huerga I, Patel JD, Aggarwal C
doi: 10.1016/j.cllc.2025.05.007
RECOMMENDED
Lung Cancer
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Gelsomino F, Boni L, Tiseo M, Ricciardi S, Rocco D, Cortinovis DL, Proietto M, Cogoni A, Pasello G, Camerini A, Sperandi F, Colantonio I, Metro G, Mazzoni F, Baldini E, Veccia A, Bennicelli E, Cecilia Bettini A, Tognetto M, Ardizzoni A
doi: 10.1016/j.lungcan.2024.108059